Jardiance Gets Heart Failure Nod, But How Long Will Its Reign Last?
Executive Summary
The SGLT2 inhibitor has better efficacy and clearer labeling than Novartis’s Entresto in heart failure with preserved ejection fraction, but AstraZeneca’s Farxiga is expected to produce Phase III data by June.